• Je něco špatně v tomto záznamu ?

Toll-like receptor dual-acting agonists are potent inducers of PBMC-produced cytokines that inhibit hepatitis B virus production in primary human hepatocytes

V. Janovec, J. Hodek, K. Clarova, T. Hofman, P. Dostalik, J. Fronek, J. Chlupac, L. Chaperot, S. Durand, TF. Baumert, I. Pichova, B. Lubyova, I. Hirsch, J. Weber

. 2020 ; 10 (1) : 12767. [pub] 20200729

Jazyk angličtina Země Velká Británie

Typ dokumentu časopisecké články, práce podpořená grantem

Perzistentní odkaz   https://www.medvik.cz/link/bmc21012337

Recombinant interferon-α (IFN-α) treatment functionally cures chronic hepatitis B virus (HBV) infection in some individuals and suppresses virus replication in hepatocytes infected in vitro. We studied the antiviral effect of conditioned media (CM) from peripheral blood mononuclear cells (PBMCs) stimulated with agonists of Toll-like receptors (TLRs) 2, 7, 8 and 9. We found that CM from PBMCs stimulated with dual-acting TLR7/8 (R848) and TLR2/7 (CL413) agonists were more potent drivers of inhibition of HBe and HBs antigen secretion from HBV-infected primary human hepatocytes (PHH) than CM from PBMCs stimulated with single-acting TLR7 (CL264) or TLR9 (CpG-B) agonists. Inhibition of HBV in PHH did not correlate with the quantity of PBMC-produced IFN-α, but it was a complex function of multiple secreted cytokines. More importantly, we found that the CM that efficiently inhibited HBV production in freshly isolated PHH via various cytokine repertoires and mechanisms did not reduce covalently closed circular (ccc)DNA levels. We confirmed our data with a cell culture model based on HepG2-NTCP cells and the plasmacytoid dendritic cell line GEN2.2. Collectively, our data show the importance of dual-acting TLR agonists inducing broad cytokine repertoires. The development of poly-specific TLR agonists provides novel opportunities towards functional HBV cure.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc21012337
003      
CZ-PrNML
005      
20210507104334.0
007      
ta
008      
210420s2020 xxk f 000 0|eng||
009      
AR
024    7_
$a 10.1038/s41598-020-69614-7 $2 doi
035    __
$a (PubMed)32728070
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxk
100    1_
$a Janovec, Vaclav $u Department of Genetics and Microbiology, Faculty of Science, Charles University, BIOCEV, 25150, Vestec, Czech Republic $u IOCB & Gilead Research Center, Institute of Organic Chemistry and Biochemistry of the Czech Academy of Science, 16610, Prague, Czech Republic
245    10
$a Toll-like receptor dual-acting agonists are potent inducers of PBMC-produced cytokines that inhibit hepatitis B virus production in primary human hepatocytes / $c V. Janovec, J. Hodek, K. Clarova, T. Hofman, P. Dostalik, J. Fronek, J. Chlupac, L. Chaperot, S. Durand, TF. Baumert, I. Pichova, B. Lubyova, I. Hirsch, J. Weber
520    9_
$a Recombinant interferon-α (IFN-α) treatment functionally cures chronic hepatitis B virus (HBV) infection in some individuals and suppresses virus replication in hepatocytes infected in vitro. We studied the antiviral effect of conditioned media (CM) from peripheral blood mononuclear cells (PBMCs) stimulated with agonists of Toll-like receptors (TLRs) 2, 7, 8 and 9. We found that CM from PBMCs stimulated with dual-acting TLR7/8 (R848) and TLR2/7 (CL413) agonists were more potent drivers of inhibition of HBe and HBs antigen secretion from HBV-infected primary human hepatocytes (PHH) than CM from PBMCs stimulated with single-acting TLR7 (CL264) or TLR9 (CpG-B) agonists. Inhibition of HBV in PHH did not correlate with the quantity of PBMC-produced IFN-α, but it was a complex function of multiple secreted cytokines. More importantly, we found that the CM that efficiently inhibited HBV production in freshly isolated PHH via various cytokine repertoires and mechanisms did not reduce covalently closed circular (ccc)DNA levels. We confirmed our data with a cell culture model based on HepG2-NTCP cells and the plasmacytoid dendritic cell line GEN2.2. Collectively, our data show the importance of dual-acting TLR agonists inducing broad cytokine repertoires. The development of poly-specific TLR agonists provides novel opportunities towards functional HBV cure.
650    _2
$a kultivační média speciální $x farmakologie $7 D017077
650    _2
$a cytokiny $x metabolismus $7 D016207
650    _2
$a kruhová DNA $x metabolismus $7 D004270
650    _2
$a systémy cílené aplikace léků $7 D016503
650    _2
$a buňky Hep G2 $7 D056945
650    _2
$a virus hepatitidy B $x fyziologie $7 D006515
650    _2
$a chronická hepatitida B $x virologie $7 D019694
650    _2
$a hepatocyty $x virologie $7 D022781
650    _2
$a lidé $7 D006801
650    _2
$a přirozená imunita $x účinky léků $7 D007113
650    _2
$a interferon alfa $x metabolismus $7 D016898
650    _2
$a leukocyty mononukleární $x metabolismus $7 D007963
650    _2
$a toll-like receptory $x agonisté $x metabolismus $7 D051193
650    _2
$a replikace viru $x účinky léků $7 D014779
655    _2
$a časopisecké články $7 D016428
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Hodek, Jan $u IOCB & Gilead Research Center, Institute of Organic Chemistry and Biochemistry of the Czech Academy of Science, 16610, Prague, Czech Republic
700    1_
$a Clarova, Kamila $u IOCB & Gilead Research Center, Institute of Organic Chemistry and Biochemistry of the Czech Academy of Science, 16610, Prague, Czech Republic
700    1_
$a Hofman, Tomas $u Department of Genetics and Microbiology, Faculty of Science, Charles University, BIOCEV, 25150, Vestec, Czech Republic $u IOCB & Gilead Research Center, Institute of Organic Chemistry and Biochemistry of the Czech Academy of Science, 16610, Prague, Czech Republic
700    1_
$a Dostalik, Pavel $u Department of Genetics and Microbiology, Faculty of Science, Charles University, BIOCEV, 25150, Vestec, Czech Republic
700    1_
$a Fronek, Jiri $u Transplantation Surgery Department, Institute for Clinical and Experimental Medicine, 14021, Prague, Czech Republic $u Department of Anatomy, Second Faculty of Medicine, Charles University, 15006, Prague, Czech Republic
700    1_
$a Chlupac, Jaroslav $u Transplantation Surgery Department, Institute for Clinical and Experimental Medicine, 14021, Prague, Czech Republic $u Department of Anatomy, Second Faculty of Medicine, Charles University, 15006, Prague, Czech Republic
700    1_
$a Chaperot, Laurence $u CNRS UMR5309, Inserm U1209, CHU Grenoble Alpes, IAB, EFS, Université Grenoble Alpes, 38000, Grenoble, France
700    1_
$a Durand, Sarah $u Inserm, Institut de Recherche Sur Les Maladies Virales Et Hepatiques UMRS 1110, Universite de Strasbourg, 67000, Strasbourg, France
700    1_
$a Baumert, Thomas F $u Inserm, Institut de Recherche Sur Les Maladies Virales Et Hepatiques UMRS 1110, Universite de Strasbourg, 67000, Strasbourg, France $u Pole Hepato-Digestif, Institut Hospitalo-Universitaire, Hopitaux Universitaires de Strasbourg, 67000, Strasbourg, France
700    1_
$a Pichova, Iva $u IOCB & Gilead Research Center, Institute of Organic Chemistry and Biochemistry of the Czech Academy of Science, 16610, Prague, Czech Republic
700    1_
$a Lubyova, Barbora $u IOCB & Gilead Research Center, Institute of Organic Chemistry and Biochemistry of the Czech Academy of Science, 16610, Prague, Czech Republic
700    1_
$a Hirsch, Ivan $u Department of Genetics and Microbiology, Faculty of Science, Charles University, BIOCEV, 25150, Vestec, Czech Republic. hirschi@natur.cuni.cz $u IOCB & Gilead Research Center, Institute of Organic Chemistry and Biochemistry of the Czech Academy of Science, 16610, Prague, Czech Republic. hirschi@natur.cuni.cz $u Institute of Molecular Genetics of the Czech Academy of Sciences, 14220, Prague, Czech Republic. hirschi@natur.cuni.cz
700    1_
$a Weber, Jan $u IOCB & Gilead Research Center, Institute of Organic Chemistry and Biochemistry of the Czech Academy of Science, 16610, Prague, Czech Republic. weber@uochb.cas.cz
773    0_
$w MED00182195 $t Scientific reports $x 2045-2322 $g Roč. 10, č. 1 (2020), s. 12767
856    41
$u https://pubmed.ncbi.nlm.nih.gov/32728070 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y p $z 0
990    __
$a 20210420 $b ABA008
991    __
$a 20210507104332 $b ABA008
999    __
$a ok $b bmc $g 1650665 $s 1132716
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2020 $b 10 $c 1 $d 12767 $e 20200729 $i 2045-2322 $m Scientific reports $n Sci Rep $x MED00182195
LZP    __
$a Pubmed-20210420

Najít záznam

Citační ukazatele

Možnosti archivace